Treatment of recurrent thyroid cancers - Is there a light in the horizon?

Current Opinion in Oncology

Volumn 20, Issue 3, 2008, Pages 245-248

  Rovere, Rodrigo Kraft ^a   Awada, Ahmad ^a,b  

^a JULES BORDET INSTITUTE   (Belgium)

^b NONE   (Belgium)

Author keywords

Advanced thyroid cancer; Axitinib; Molecular targeted agents; Sorafenib; Sunitinib

Indexed keywords

AXITINIB; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; IODINE 131; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; RADIOACTIVE IODINE; SORAFENIB; SUNITINIB; THYROTROPIN; VANDETANIB; VASCULOTROPIN RECEPTOR 2;

ANAPLASTIC CARCINOMA; CALCITONIN BLOOD LEVEL; CANCER INHIBITION; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXICITY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ACTIVITY; DRUG EFFECT; DRUG TOLERABILITY; FATIGUE; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INCIDENCE; LOBECTOMY; LYMPHADENECTOMY; MUCOSA INFLAMMATION; NAUSEA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RASH; RECURRENT CANCER; REVIEW; STOMATITIS; THYROID CANCER; THYROIDECTOMY; TREATMENT RESPONSE; TUMOR REGRESSION;

EID: 41949131552     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3282fb289a     Document Type: Review

References (23)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2006. Cancer J Clin 2006; 56:106-130.
2. Ries LAG, Eisner MP, Kosary, CL, et al. SEER Cancer Statistics Review 1975-2001, National Cancer Institute, Bethesda, MD. Available at http://seer.cancer.gov. Accessed 22 October 2007.
3. Gilliland FD, Hunt WC, Morris DM, et al. Prognostic factors for thyroid carcinoma. A population-based study of 15 698 cases from the Surveillance, Epidemiology and End Results (SEER) program, 1973-1991. Cancer 1997; 79:564.
4. Chan T, Yau R. Epstein RJ, et al. Treatment outcomes in anaplastic thyroid carcinoma from 1966-2006: Failure of overall survival enhancement despite four decades of progress in surgery, radiotherapy and chemoradiation. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 20 June 2007; 25, (Suppl 18): 2007: 16537.
5. Vini L, Harmer C. Management of thyroid cancer. Lancet Oncol 2002; 3:407-414.
6. Shimaoka K, Schoenfeld DA, DeWys WD, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985; 56:2155.
7. Gottlieb JA, Hill CS Jr. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med 1974; 290:193.
8. Williams SD, Birch R, Einhorn LH. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep 1986; 70:405.
9. Wong JB, Kaplan MM, Meyer KB, et al. Ablative radioactive iodine therapy for apparently localized thyroid carcinoma: a decision analytic perspective. Endocrinol Metab Clin North Am 1990; 19:741.
10. Sawka AM, Thephamongkhol K, Brouwers M, et al. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well differentiated thyroid cancer. J Clin Endocrinol Metab 2004; 89:3668.
11. Farahati J, Reiners C, Stuschke M, et al. Differentiated thyroid cancer. Impact of adjuvant external radiotherapy in patients with perithyroidal tumour infiltration (stage pT4). Cancer 1996; 77:172-180.
12. Phlips P, Hanzen C, Andry G, et al. Postoperative irradiation for thyroid cancer. Eur J Surg Oncol 1993; 19:399-404.
13. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 1981; 70:511-518.
14. Lim S, Lee NY, Fury MG, et al. Doxorubicin and concurrent radiotherapy for anaplastic thyroid cancer: We need to do better. Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings Part I 20 June 2007; 25 (Suppl 18): 2007: 16506.
15. Hipp MM, Hilf N, Walter S, et al. Sorafenib but not sunitinib affects the induction of immune responses. Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings Part I 20 June 2007; 25 (Suppl 18): 3504.
16. Rini BI, Wilding GT, Hudes G. et al. Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib. Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings Part I 20 June 2007; 25 (Suppl 18): 5032.
17. Tamaskar R, Unnithan J, Garcia JA, et al. Thyroid function test (TFT) abnormalities in patients (pts) with metastatic renal cell carcinoma (RCC) treated with sorafenib. Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings Part I 20 June 2007; 25 (Suppl 18): 5048.
18. Gupta V, Puttaswamy K, Lassoued W, et al. Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma. Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings Part I 20 June 2007; 25 (Suppl 18): 6019 Sorafenib showed promising clinical benefit rate in more than 70% of patients.
19. Kober F, Hermann M, Handler A, et al. Effect of sorafenib in symptomatic metastatic medullary thyroid cancer. Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings Part I 20 June 2007; 25 (Suppl 18): 14065.
20. Pennell NA, Daniels GH, Haddad RI, et al. A phase II study of gefitinib in patients with advanced thyroid cancer. Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings Part I 20 June 2007; 25(Suppl 18): 6020.
21. Wells SA, Gosnell JE, Gagel RF, et al. Vandetanib in metastatic hereditary medullary thyroid cancer: Follow-up results of an open-label phase II trial. Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings Part I 20 June 2007; 25 (Suppl 18): 6018.
22. Cohen EE, Vokes EE, Rosen LS, et al. A phase II study of axitinib (AG-013736 [AG]) in patients (pts) with advanced thyroid cancers. Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings Part I 20 June 2007; 25(Suppl 18): 6008. Interesting tumour regression rate observed in different histologies of advanced thyroid cancer with a promising response duration.
23. Sherman SI, Schlumberger MJ, Droz J, et al. Initial results from a phase II trial of motesanib diphosphate (AMG 706) in patients with differentiated thyroid cancer (DTC). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 20 June 2007; 25(Suppl 18): 6017.